Pembrolizumab Injection: Lowest Cost & Info Hub | Rajampet| Andhra Pradesh| India
Drug Category
Immunotherapy
Drug name
Pembrolizumab
Complete Drug Name
Pembrolizumab Injection
Mode of Delivery
Injection
Brand
Brand name: Keytruda Manufacturer: Merck & Co., Inc.
Dosage/Dose
Pembrolizumab dosage: 200 mg IV every 3 weeks (Q3W)
Types of Cancer & Indication
Pembrolizumab is sanctioned for numerous malignancies, including melanoma, non-small cell lung cancer, head and neck squamous cell cancer, classical Hodgkin lymphoma, urothelial carcinoma, gastric cancer, esophageal cancer, and cancers with microsatellite instability or mismatch repair deficiency. Indications entail immune-based intervention to stimulate anti-tumor responses.
Mechanism of Action
Pembrolizumab is an innovative immunotherapy that empowers a patient's immune system to target and combat cancer cells. It works by inhibiting the PD-1 protein, which cancer cells exploit to dodge immune defenses. By blocking this evasive tactic, pembrolizumab allows immune cells to recognize and destroy malignant cells. Versatile in its application, pembrolizumab has displayed efficacy in various cancer types, heralding a new era of therapeutic hope.
Mechanism of Resistance
Pembrolizumab resistance arises when tumor cells evade immune checkpoint inhibition by altering their molecular landscape, causing impaired T-cell activation, reduced tumor antigen presentation, and elevated immunosuppressive factors. This hampers pembrolizumab's functionality, diminishing its cancer-fighting efficacy.
Side Effects
Pembrolizumab injection may cause a range of adverse reactions, such as fatigue, cough, nausea, and itching. Some individuals might experience more severe effects, including immune system attacks on healthy organs, lung inflammation, liver problems, or life-threatening infusion reactions. Regular monitoring is vital to detect these issues early.
Combination Therapy
Pembrolizumab can be employed alongside various medications depending on the specific cancer type. For instance, pemetrexed and platinum-based chemotherapy (cisplatin or carboplatin) are often combined with pembrolizumab for treating non-squamous non-small cell lung cancer (NSCLC). Additionally, pembrolizumab is FDA-approved for pairing with axitinib to address advanced renal cell carcinoma (RCC). Always consult a healthcare professional for personalized treatment decisions.
Final Cost
Pembrolizumab Injection avg. cost in India: ₹75,000. The above price is specific for Rajampet, Andhra Pradesh, India